APA-viite (7. p.)

Dutton, S., Blazeby, J., Petty, R., Mansoor, W., Thompson, J., Harrison, M., . . . Grp, C. (2013). Patient-reported outcomes from a phase HI multicenter, randomized, double-blind, placebo-controlled trial of gefitinib versus placebo in esophageal cancer progressing alter chemotherapy: Cancer Oesophagus Gefitinib (COG).

Chicago-viite (17. p.)

Dutton, S., et al. Patient-reported Outcomes from a Phase HI Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Gefitinib Versus Placebo in Esophageal Cancer Progressing Alter Chemotherapy: Cancer Oesophagus Gefitinib (COG). 2013.

MLA-viite (9. p.)

Dutton, S., et al. Patient-reported Outcomes from a Phase HI Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Gefitinib Versus Placebo in Esophageal Cancer Progressing Alter Chemotherapy: Cancer Oesophagus Gefitinib (COG). 2013.

Varoitus: Nämä viitteet eivät aina ole täysin luotettavia.